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BACKGROUND. Prior studies have determined that macroscopic (“gross”) tumor
volume (GTV), as calculated from pretreatment computer tomography (CT), was
capable of predicting local control in squamous cell carcinoma arising in different
subsites in the head and neck in patients who were treated with nonsurgical
organ-preservation therapy. The majority of these studies were single-institution,
retrospective investigations. Consequently, there has been concern that GTV mea-
surements may not be reproducible by different readers at different institutions.
The objective of the current study was to measure the interobserver reliability for
GTV measurements for squamous cell carcinoma of the supraglottic larynx (SG-
SCCA) performed by different readers at different institutions.
METHODS. Eight experienced readers (4 neuroradiologists and 4 radiation oncolo-
gists) from different institutions independently measured the pretreatment GTV of
20 patients with SGSCCA. The CT scans were obtained from patients entered into
the definitive radiation therapy arm of Radiation Therapy Oncology Group proto-
col 91-11, who had supraglottic carcinoma and underwent pretreatment CT scans
of the neck. Statistical analysis focused on interobserver reliability as measured by
the intraclass correlation coefficient.
RESULTS. The intraclass correlation coefficient was 0.81 (95% lower confidence
bound, 0.71). This value was interpreted as “excellent.”
CONCLUSIONS. GTV measurements were reliable and reproducible when per-
formed by neuroradiologists and radiation oncologists who were experienced in
the interpretation of CT scans of the extracranial head and neck in patients with
SGSCCA. The result implied that the correlation between GTV and local control
should be reproducible across institutions. Cancer 2005;103:2616 –22.
© 2005 American Cancer Society.
KEYWORDS: cancer, tumor volume, CT, squamous cell cancer, head and neck,
larynx.
Nonsurgical organ-preservation therapy is a viable treatment op-tion for patients with head and neck squamous cell carcinoma
(HNSCCA).
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The final decision for each individual frequently is
basedon an overall assessment of the risk of local
recurrence, 5-year survival, treatment-associated
morbidity, and institutional and patient preference.
In many disease sites, it has been shown that
cross-sectional imaging is more accurate than physi-
cal examination for assessing primary tumor size and
extent.1–3 Consequently, pretreatment imaging has
become an accepted part of staging and, as stated in
the American Joint Committee on Cancer Staging
Manual, any diagnostic information that may contrib-
ute to the overall accuracy of a pretreatment assess-
ment should be taken into consideration in clinical
staging and treatment planning.4
Numerous studies have shown that the macro-
scopic (“gross”) tumor volume (GTV) at the primary
site, as calculated from pretreatment computed to-
mography (CT) scans, can predict local control in
squamous cell carcinoma (SCC) arising in different
subsites of the head and neck in patients who are
treated with definitive radiation therapy (RT).5–17
Larger volume tumors have a higher likelihood of local
recurrence than smaller volume lesions arising in the
same anatomic subsite.5–17 Threshold volumes have
been identified in nasopharyngeal, oropharyngeal, su-
praglottic, pyriform sinus, and T3 glottic carcino-
mas.5–17 Several investigators also have shown that
there is a stronger association between GTV and local
control than the association between T classification
and local control.6,7,15–18 This additional information
helps physicians to counsel patients regarding the rel-
ative likelihood of local tumor control with primary
surgery or RT with or without chemotherapy. In regard
to laryngeal carcinoma, information regarding the rel-
ative risk of local failure based on an objective, quan-
titative measure of GTV may assist patients in deter-
mining the risk they are willing to assume to preserve
native laryngeal function. Quantitative volumetric
analysis also may help select patients with larger vol-
ume tumors who either desire organ-preservation
therapy or who are poor surgical candidates for neo-
adjuvant or concurrent chemotherapy.
One drawback of integrating GTV measurements
into treatment decisions is concern regarding the re-
producibility of GTV measurements performed by dif-
ferent observers at different institutions. There is
some doubt that GTV measurements can be repro-
duced reliably when they are performed by different
subspecialists at different institutions. This concern
has reduced the acceptance of integrating this concept
into treatment and management decisions. An inac-
curate GTV measurement has the potential to misrep-
resent the likelihood of nonsurgical local control and
adversely affect treatment decisions. In view of this,
the objective of the current investigation was to cal-
culate the interobserver variability of GTV measure-
ments in patients with primary site SCC of the supra-
glottic larynx (SGSCCA) performed by different
readers at different institutions.
MATERIALS AND METHODS
Patient Accrual
This trial was supported by the American College of
Radiology Imaging Network (ACRIN) (protocol 6658).
ACRIN protocol 6658 was approved by the Institu-
tional Review Board (IRB) of the American College of
Radiology and by the National Cancer Institute Cancer
Therapy Evaluation Program. The patient population
consisted of a subset of patients entered into Radia-
tion Therapy Oncology Group (RTOG) protocol 91-11
between 1992 and 2000. All patients eligible for ACRIN
protocol 6658 had SGSCCA and had been randomized
to the “definitive RT only” arm of RTOG 91-11. In-
formed consent for RTOG 91-11 included consent for
subsequent research as long as patient confidentiality
was maintained.
RTOG member institutions and affiliates that had
accrued at least one potential patient were asked to
submit the protocol to their local IRB. Upon notice of
local IRB approval, ACRIN requested materials for ap-
propriate patients. Institutions then submitted avail-
able case material, including pretreatment CT studies.
ACRIN obtained from the RTOG a list of 93 poten-
tially eligible patients enrolled at 41 institutions. Eight
institutions (20%) with a total of 36 eligible patients
(39%) obtained local IRB approval. Images were ob-
tained for 28 eligible patients (78% of the 36 requested;
3 images were lost, 3 images were unavailable and
presumed destroyed, 1 institution chose not to recon-
sent a Veterans Administration patient, and 1 institu-
tion with 1 eligible patient did not return the request
form). The principal investigator reviewed the image
quality for inclusion into the study. Images from 4
patients (14%) did not pass this quality review (for 3
patients the image was of the wrong primary tumor
location, and for 1 patient only a poor-quality image
was available, with the institution unable to obtain a
better quality copy). The principal investigator then
reviewed the 24 sets of images that passed initial qual-
ity review, selecting 4 as training cases (2 with subop-
timal copy quality, 1 with labels on films, and 1 with
nonremovable wax crayon on films), and 20 patients
for the study sample. The four training cases were
used to familiarize the reader with the presentation of
the imaging format, software capabilities, and use of
the mouse to contour the outer margin of the tumor.
Of the 20 patients in the study sample who were
eligible; 55% were male and 75% were white, with a
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median age of 56 years (range, 40 –72 years). The low-
est Karnofsky performance status was 70 (15%), and 1
patient (5%) had a Karnofsky performance status of
100. Fifty-five percent of the study patients presented
with weight loss (maximum, 12 kg). There were no
statistically significant differences noted between the
study sample and the remainder of the original 93
potential patients with respect to age, ethnicity, gen-
der, Karnofsky performance status, proportion who
presented with weight loss, or amount of weight lost
among those with this symptom.
CT Studies
The CT studies consisted of contrast-enhanced studies
that were performed in patients who were entered
prospectively into RTOG 91-11 between 1992 and
2000. The CT imaging protocol consisted of contigu-
ous, 5-mm-thick sections from the skull base to the
thoracic inlet. It was believed that this slice thickness
was adequate at the time the protocol was initiated.
Because our request for the CT studies was made after
the studies already had been performed, we were un-
able to modify the CT imaging protocol to incorporate
recent technical advances.
All original CT studies were hard-copy films.
These studies were digitized using a Kodak laser scan-
ner (Eastman Kodak, Rochester, NY) and were post-
processed for display and analysis using a proprietary
software package. Each image on each sheet of film
was digitized and stacked sequentially. The software
automatically accounted for any potential differences
in slice thickness, table spacing, and field of view to
ensure accurate measurements.
Readers
Eight readers independently interpreted the CT image
from each patient in the study sample. The readers
came from educational institutions and had a range of
2–25 years of experience in interpreting imaging stud-
ies or managing patients with HNSCCA. Four readers
were neuroradiologists who had dedicated training in
head and neck radiology by working with an experi-
enced head and neck radiologist during their neuro-
radiology fellowship. Three of the four neuroradiolo-
gists had a certificate of added qualification. The other
four readers were radiation oncologists with experi-
ence in the treatment of HNSCC. Readers provided a
rating of the quality of each CT study by selecting from
excellent diagnostic quality, very good diagnostic
quality, average diagnostic quality, below average di-
agnostic quality, or poor diagnostic quality. Readers
reported tumor location by selecting from epiglottis,
aryepiglottic folds, arytenoids, ventricular bands, or
unable to determine. The site of origin was selected
from right, left, midline, or unable to determine.
Volume Analysis
Volumetric analysis was performed on all tumors in
the following manner: The interpretation and con-
touring was performed using a Microsoft Windows-
based personal computer (Microsoft Inc., Redmond,
WA) with dual 2 K  2 K, high-resolution monitors and
running BITImage software for viewing CT images and
making the volumetric measurements. For every CT
study, each reader manually used a “mouse” to con-
tour the outer margin of any abnormal laryngeal mass
on each image that they believed was suspicious of
demonstrating a primary SGSCCA site. (Fig. 1) The
patient entry criteria into RTOG 91-11 excluded early-
stage T1 and advanced-stage T4 tumors that extended
through the cartilage and into the soft tissues of the
neck. Consequently, all the tumors measured in our
study were confined to the larynx, and no tumor ex-
tended into the soft tissues of the neck. After comple-
tion of the contouring, the tumor volume was calcu-
lated automatically from our software package by
incorporating the area contoured on each image. The
software automatically accounted for differences in
slice thickness, table spacing, and field of view for
each study to ensure accurate tumor volume measure-
ments, as discussed above.
Statistical Analysis
The primary statistical endpoint was interreader reli-
ability for the evaluation of GTV, as measured by the
intraclass correlation coefficient (ICC). The ICC and a
95% lower confidence bound for the ICC were esti-
mated using a two-way analysis of variance (ANOVA)
with log10 (GTV) as the dependent variable and with
random effects for patients and readers.19 We use log10
(GTV) instead of GTV, because the distribution of log10
(GTV) values is more symmetric than the distribution
of GTV values, and the spread of observed log10 (GTV)
values for each tumor is more stable over the range of
actual tumor sizes. In part of the secondary analyses
for this study, generalized  statistics were computed
to evaluate interreader reliability in impressions of
image quality and tumor location.20 Reliability statis-
tics often are interpreted as “poor” if  0.00, “slight” if
0.00 – 0.20, “fair” if 0.21– 0.40, “moderate” if 0.41– 0.60,
“substantial” if 0.61– 0.80, and “almost perfect” if 0.81–
1.00.21 In addition, we used a mixed-model ANOVA to
explore differences in log10 (GTV) measurements be-
tween the 2 groups of subspecialists that interpreted
the studies.
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RESULTS
In total, 160 CT interpretations (20 patients and 8 read-
ers) were performed at a central reading site from May
29, 2002 through September 7, 2002. Study readers pre-
dominantly rated image quality as “average” or “very
good,” with 116 ratings (72.5%) that were at least aver-
age. The proportion of observed agreement among 8
readers for image quality on a 5-point scale was 0.36,
increasing to 0.84 when adjacent categories were con-
sidered to be in agreement; reliability beyond chance
was slight (  0.11; standard error [SE]  0.03).
One reader (Reader 5) could not identify the tu-
mor for 1 patient (Patient 6) and therefore did not
provide information on primary site, site of origin, or
tumor volume. This tumor was identified by the other
seven readers and had the smallest median volume
among the study sample. The primary site was noted
as epiglottis in 77 ratings (48%), aryepiglottic fold in 45
ratings (28%), false vocal cord in 25 ratings (16%),
unable to determine in 12 ratings (16%), and arytenoid
in 1 reading. The site of origin was noted as midline in
60 ratings (38%), left side in 57 ratings (36%), right side
in 37 ratings (23%), and unable to determine in 6
ratings (4%). The proportion of observed agreement
for location (epiglottis, aryepiglottic fold, false vocal
cord, unable to determine) was 0.58; reliability beyond
chance was fair (  0.36; SE  0.03). The proportion
of observed agreement for site of origin (left, right,
midline, unable to determine) was 0.73; reliability be-
yond chance was moderate (  0.59; SE  0.03).
The median tumor volume among the 159 CT
interpretations obtained was 9.77 cm3 (range, 0.31–
46.84 cm3). The ICC for log10 GTV, which measures
interreader reliability, was 0.81, with a 95% lower con-
fidence bound of 0.71. These values are interpreted as
“almost perfect” (0.81) and “substantial” (0.71). Fig-
ures 2 and 3 display the distributions of GTV for each
reader and for each patient, respectively. The high
degree of overlap across readers and the narrow dis-
tributions within each patient reflect the high inter-
reader reliability for measuring GTV.
The overall median GTV measurements differed
between neuroradiologists and radiation oncologists.
The median GTV was 8.3 cc when measured by diag-
nostic neuroradiologists and 11.5 cc when measured
by radiation oncologists. This difference was signifi-
cant (P  0.02). The ICC for log10 GTV was measured
for the subgroups of radiologists and radiation oncolo-
gists. The ICC for neuroradiologists was 0.84 (95%
lower confidence bound of 0.74), whereas the ICC for
radiation oncologists was 0.88 (95% lower confidence
bound, 0.79); the difference between the ICC for neu-
roradiologists and radiation oncologists was not sig-
nificant. Figure 4 displays the distribution of GTV for
each reader grouped by subspecialty. The horizontal
FIGURE 1. This axial, contrast-enhanced computed tomography scan, which
was obtained at the level of the thyroid cartilage in a patient with a right
aryepiglottic fold squamous cell carcinoma, demonstrates a mass involving the
right aryepiglottic fold. The tumor contour drawn by Reader 1 is shown in this
illustration.
FIGURE 2. Measurements of macroscopic tumor volume were provided by
study readers for patients. Each box contains the center 50% of the volumes
for each reader; the white bar within the box indicates the median. The asterisk
indicates the radiation oncologist who could not identify one of the tumors. The
solid lines extending above and below each box indicates the range of volumes
except for Reader 2, who provided a very small volume for one patient, as
indicated by the small line near the bottom of the figure.
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lines indicate the median GTV for each group. The
similarity in the sizes of the boxes reflects the consis-
tency in variability over all of the readers. Figure 5
displays the range of GTV measurements for each case
by subspecialty. The similarity in the lengths of the
lines indicated that the variability is similar between
the two groups. The fact that the solid lines generally
are higher reflects the fact that the radiation oncolo-
gists’ tumor volume measurements tended to be
higher.
DISCUSSION
The results of our investigation demonstrate that GTV
derived from CT studies can be measured reliably
across readers. The estimated ICC of 0.81 commonly is
considered excellent. These findings indicate that re-
producible GTV measurements can be obtained
across different institutions and different subspecial-
ties.
In 1998, Hermans et al.22 reported on intraob-
server and interobserver reliability of GTV measure-
ments using 13 laryngeal tumors (including 5 supra-
glottic carcinomas) that were evaluated 4 times by
each of 5 readers. In the current study, 8 readers
evaluated 20 supraglottic carcinomas once. The tu-
mors in our series tended to be larger in volume. Due
to study design, the statistical analyses performed for
the two studies differed. Hermans et al. generously
supplied us their data, which we used to obtain inter-
observer ICCs for each of the 4 readings, which ranged
from 0.75 to 0.82. Therefore, our results are similar to
the ICCs obtained from the data of Hermans et al.22
Our readers consisted of both neuroradiologists
and radiation oncologists who were experienced in the
treatment of HNSCCA. We believed that it was impor-
tant to include both groups to emphasize the interdis-
ciplinary approach for the management and treat-
ment of HNSCCA. GTV measurements may be
FIGURE 3. Measurements of macroscopic tumor volume for each patient
were provided by the study readers. Each box contains the center 50% of the
volumes for each patient; the white bar within the box indicates the median.
The asterisk indicates a patient for whom one radiation oncologist could not
identify a tumor. The solid lines extending above and below each box indicate
the range of volumes for each patient. For Patients 6, 9, 10, and 12, 1 reader
provided a volume that was notably smaller than the volume reported by other
readers, as indicated by the small lines that are not connected to the boxes.
FIGURE 4. Measurements of macroscopic tumor volume provided by study
readers for patients are organized by reader type. Horizontal lines indicate the
median volume for each group. Each box contains the center 50% of volumes
for each reader; the white bar within the box indicates the median. The dashed
lines extending above and below each box indicate the range of volumes for
each reader, except for Reader 2, who provided a very small volume for one
patient, as indicated by the small line near the bottom of the figure. The
asterisk indicates the radiation oncologist who could not identify one of the
tumors.
FIGURE 5. Measurements of macroscopic tumor volume are organized by
patient and by the subspecialty of the reader. Line segments indicate the range
of the four measurements per patient and subspecialty. The asterisk indicates
a patient for whom one radiation oncologist could not identify a tumor.
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performed by either radiologists or radiation oncolo-
gists, depending on the institution. GTV may be cal-
culated for initial evaluation by neuroradiologists. Tu-
mor contouring for RT planning is performed by
radiation oncologists for either definitive or adjuvant
treatment. Because both groups are involved in tumor
contouring and volume measurements, we believed
that it was important to determine interobserver vari-
ability not only between institutions but also between
specialists involved in the management of these pa-
tients. The overall ICC for our study was 0.81 (“excel-
lent”). The estimated ICCs were similar for each sub-
specialty and were higher than the overall ICC,
indicating that neuroradiologists were more likely to
measure like other neuroradiologists than like radia-
tion oncologists, and vice versa.
Exploratory data analysis showed that the median
GTV measurement was slightly larger for radiation
oncologists than for the neuroradiologists. This un-
usual finding needs to be confirmed in a prospective
study, because it does have potential implications in
clinical practice: Most published data were based on
work done by radiologists. Unfortunately, there is no
reliable method for identifying the true GTV of an in
vivo tumor accurately, because the size of the tumor
will change once it is devascularized and removed
from the patient. Thus, it is not possible to determine
whether the neuroradiologists or radiation oncologists
had the more accurate measurements. The potential
effect on management, based on measurements ob-
tained by different subspecialists, would need to be
evaluated in a large-scale, prospective investigation.
Radiation oncologists may estimate larger sizes based
on their common use of endoscopy, which reveals the
tumor’s surface anatomy, which is not seen on CT.
Subconsciously, radiation oncologists may add a con-
ceptual volume to the volume estimated solely from
CT to compensate. Radiation oncologists may tend to
be more inclusive and “round off” irregular edges of a
tumor, as assessed by CT, to conform with their ideas
of tumor growth, whereas diagnostic radiologists may
contour exactly what they see. Unfortunately, in the
current study, we could not differentiate between
these possibilities and could not resolve the issue;
however, it does raise questions that need to be ad-
dressed in future trials. Currently, in the absence of a
true gold standard, it appears that patients are served
ideally when their tumors are evaluated by a multidis-
ciplinary group, potentially diluting any individual
group’s tendencies.
Specific imaging parameters appear to be strong
predictors of local and locoregional outcome in pa-
tients with supraglottic carcinoma who are treated by
definitive RT. GTV appears to be the strongest inde-
pendent predictor of local failure after RT.9 Pretreat-
ment CT measurements of GTV permit stratification of
local control in patients with SGSCCA who receive
treatment with RT alone. Mancuso et al. reported local
control rates of 89% in tumors  6 cc and 52% when
tumor volumes were  6 cc. Some authors suggest
that SGSCCA with a GTV  16 cc should be treated
with surgical resection only.14,15 The specific threshold
volume may vary; however, what is of greater impor-
tance is the linear relation between tumor volume and
local control, as reported by Mancuso et al. Based on
this relation, a more accurate estimate of cure can be
obtained for each individual patient rather than rely-
ing on general threshold measurements.9 Therefore,
consistent and reproducible measurements are im-
portant when attempting to quantify GTV. Large vari-
ability in GTV measurements may result in an errone-
ous classification of a tumor as too large to be treated
successfully with definitive RT.
A limitation of the current study was that the CT
protocol was not optimized for slice thickness, gantry
angle, or helical acquisition. Current recommenda-
tions for imaging studies in patients with laryngeal
carcinoma include a slice thickness  3 mm, a gantry
angle that is parallel to the laryngeal ventricle, and the
image acquisition should be performed with a multi-
detector scanner. The CT studies were performed on
patients that prospectively entered RTOG study 91-11
between 1992 and 2000. Because our request for these
CT studies was made after the CT already had been
performed, we were unable to modify the CT imaging
protocol by incorporating current techniques and
concepts. Despite the fact that an optimized protocol
was not used, we feel comfortable that the available
imaging studies can be used to measure interobserver
variability for GTV measurements.
The results of the current study indicate that re-
producible GTV measurements can be obtained at
different institutions by both neuroradiologists and
radiation oncologists. All readers should be knowl-
edgeable with the appearance of normal anatomy,
common tumor behavior, and pathology of the head
and neck to obtain accurate and reproducible mea-
surements. Multidisciplinary evaluation teams appear
to provide the greatest level of comfort, so that an
accurate measurement of tumor volume is obtained.
However, for tumors that are substantially larger or
substantially smaller than the quasithreshold of suit-
ability, for nonsurgical management, our results sug-
gest that experienced diagnostic radiologists and radi-
ation oncologists agree that assessment by either
subspecialty should lead to the correct assessment.
Given these findings, we believe that primary site GTV
information can be taken into account reliably when
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considering treatment options in patients with SG-
SCCA.
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